149 related articles for article (PubMed ID: 37085425)
1. Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel.
Lara PN; Mayerson E; Gertz E; Tangen C; Goldkorn A; van Loan M; Hussain M; Gupta S; Zhang J; Parikh M; Twardowski P; Quinn DI; LeBlanc M; Vogelzang NJ; Thompson I; Agarwal N
Eur Urol; 2024 Feb; 85(2):171-176. PubMed ID: 37085425
[TBL] [Abstract][Full Text] [Related]
2. Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel.
Lara PN; Mayerson E; Gertz E; Tangen C; Goldkorn A; van Loan M; Hussain M; Gupta S; Zhang J; Parikh M; Twardowski P; Quinn DI; LeBlanc M; Thompson I; Agarwal N
Prostate Cancer Prostatic Dis; 2024 Feb; ():. PubMed ID: 38424319
[TBL] [Abstract][Full Text] [Related]
3. Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide.
Parikh M; Tangen C; Hussain MHA; Gupta S; Callis S; Jo Y; Harzstark A; Paller CJ; George S; Zibelman MR; Cheng HH; Maughan BL; Zhang J; Pachynski RK; Bryce AH; Lin DW; Quinn DI; Lerner SP; Thompson IM; Dorff TB; Lara PN; Agarwal N
Eur Urol Oncol; 2024 Mar; ():. PubMed ID: 38523017
[TBL] [Abstract][Full Text] [Related]
4. Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).
Agarwal N; Tangen CM; Hussain MHA; Gupta S; Plets M; Lara PN; Harzstark AL; Twardowski PW; Paller CJ; Zylla D; Zibelman MR; Levine E; Roth BJ; Goldkorn A; Vaena DA; Kohli M; Crispino T; Vogelzang NJ; Thompson IM; Quinn DI
J Clin Oncol; 2022 Oct; 40(28):3301-3309. PubMed ID: 35446628
[TBL] [Abstract][Full Text] [Related]
5. Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421.
Lara PN; Plets M; Tangen C; Gertz E; Vogelzang NJ; Hussain M; Twardowski PW; Garzotto MG; Monk JP; Carducci M; Goldkorn A; Mack PC; Thompson I; Van Loan M; Quinn DI
Cancer Treat Res Commun; 2018; 16():18-23. PubMed ID: 31298998
[TBL] [Abstract][Full Text] [Related]
6. The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.
Armstrong AJ; Iguchi T; Azad AA; Villers A; Alekseev B; Petrylak DP; Szmulewitz RZ; Alcaraz A; Shore ND; Holzbeierlein J; Gomez-Veiga F; Rosbrook B; Zohren F; Haas GP; Gourgiotti G; El-Chaar N; Stenzl A
Eur Urol; 2023 Aug; 84(2):229-241. PubMed ID: 37179240
[TBL] [Abstract][Full Text] [Related]
7. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.
Lara PN; Ely B; Quinn DI; Mack PC; Tangen C; Gertz E; Twardowski PW; Goldkorn A; Hussain M; Vogelzang NJ; Thompson IM; Van Loan MD
J Natl Cancer Inst; 2014 Apr; 106(4):dju013. PubMed ID: 24565955
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
[TBL] [Abstract][Full Text] [Related]
9. Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial.
Sayegh N; Swami U; Jo Y; Gebrael G; Haaland B; Gupta S; Plets M; Hussain MHA; Quinn DI; Lara PN; Thompson IM; Agarwal N
JAMA Netw Open; 2023 Aug; 6(8):e2326546. PubMed ID: 37526936
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
Yanagisawa T; Rajwa P; Kawada T; Mori K; Fukuokaya W; Petrov P; Quhal F; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pradere B; Kramer G; Kimura T; Shariat SF
J Urol; 2023 Sep; 210(3):416-429. PubMed ID: 37339479
[TBL] [Abstract][Full Text] [Related]
11. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
Saad F; Fizazi K; Jinga V; Efstathiou E; Fong PC; Hart LL; Jones R; McDermott R; Wirth M; Suzuki K; MacLean DB; Wang L; Akaza H; Nelson J; Scher HI; Dreicer R; Webb IJ; de Wit R;
Lancet Oncol; 2015 Mar; 16(3):338-48. PubMed ID: 25701170
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan.
Narita S; Hatakeyama S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Koizumi A; Mitsuzuka K; Tochigi T; Tsuchiya N; Ohyama C; Arai Y; Nomura K; Habuchi T
Int J Clin Oncol; 2020 May; 25(5):912-920. PubMed ID: 31919691
[TBL] [Abstract][Full Text] [Related]
13. Lower pretreatment serum testosterone level predicts poor prognosis in the patients with metastatic hormone-sensitive prostate cancer undergoing androgen deprivation therapy.
Yoshida T; Kawai T; Hagiwara K; Yanagida K; Noda M; Tokura Y; Yoshimura I; Kaneko T; Nakagawa T
Jpn J Clin Oncol; 2024 Apr; 54(4):498-503. PubMed ID: 38251778
[TBL] [Abstract][Full Text] [Related]
14. Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event.
Hahn NM; Yiannoutsos CT; Kirkpatrick K; Sharma J; Sweeney CJ
Clin Genitourin Cancer; 2014 Feb; 12(1):33-40.e4. PubMed ID: 24126237
[TBL] [Abstract][Full Text] [Related]
15. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.
Stein MN; Patel N; Bershadskiy A; Sokoloff A; Singer EA
Asian J Androl; 2014; 16(3):387-400. PubMed ID: 24759590
[TBL] [Abstract][Full Text] [Related]
16. External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer.
Swami U; Sayegh N; Jo Y; Haaland B; McFarland TR; Nussenzveig RH; Goel D; Sirohi D; Hahn AW; Maughan BL; Goldkorn A; Agarwal N
Mol Cancer Ther; 2022 Dec; 21(12):1857-1861. PubMed ID: 36198026
[TBL] [Abstract][Full Text] [Related]
17. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
Mehra N; Dolling D; Sumanasuriya S; Christova R; Pope L; Carreira S; Seed G; Yuan W; Goodall J; Hall E; Flohr P; Boysen G; Bianchini D; Sartor O; Eisenberger MA; Fizazi K; Oudard S; Chadjaa M; Macé S; de Bono JS
Eur Urol; 2018 Sep; 74(3):283-291. PubMed ID: 29500065
[TBL] [Abstract][Full Text] [Related]
18. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
James ND; Spears MR; Clarke NW; Dearnaley DP; De Bono JS; Gale J; Hetherington J; Hoskin PJ; Jones RJ; Laing R; Lester JF; McLaren D; Parker CC; Parmar MKB; Ritchie AWS; Russell JM; Strebel RT; Thalmann GN; Mason MD; Sydes MR
Eur Urol; 2015 Jun; 67(6):1028-1038. PubMed ID: 25301760
[TBL] [Abstract][Full Text] [Related]
19. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
Hussain M; Tombal B; Saad F; Fizazi K; Sternberg CN; Crawford ED; Shore N; Kopyltsov E; Kalebasty AR; Bögemann M; Ye D; Cruz F; Suzuki H; Kapur S; Srinivasan S; Verholen F; Kuss I; Joensuu H; Smith MR
J Clin Oncol; 2023 Jul; 41(20):3595-3607. PubMed ID: 36795843
[TBL] [Abstract][Full Text] [Related]
20. Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11).
Cathomas R; Crabb SJ; Mark M; Winterhalder R; Rothermundt C; Elliott T; von Burg P; Kenner H; Hayoz S; Vilei SB; Rauch D; Roggero E; Mohaupt MG; Bernhard J; Manetsch G; Gillessen S;
Prostate; 2016 Dec; 76(16):1519-1527. PubMed ID: 27457964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]